Vaxart, Inc. (NASDAQ:VXRT) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET

Company Participants

Edward Berg - Senior Vice President and General Counsel

Andrei Floroiu - Chief Executive Officer

James Cummings - Chief Medical Officer

Sean Tucker - Founder & Chief Scientific Officer

Phil Lee - Chief Financial Officer

Conference Call Participants

Mayank Mamtani - B. Riley Securities

Roger Song - Jefferies

Operator

Greetings and welcome to Vaxart Business Update and First Quarter 2023 Financial Results Conference Call. A question-and-answer session will follow management's opening remarks. Individual investors may submit written questions to ir@vaxart.com. As a reminder, this conference is being recorded.

I would now like to turn the webcast over to your host, Ed Berg, Senior Vice President and General Counsel.

Edward Berg

Good afternoon, and welcome to today's call. Joining us from Vaxart are Andrei Floroiu, Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; Dr. James Cummings, Chief Medical Officer; and Phillip Lee, Chief Financial Officer.

Before we get started, I would like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations and its product development and regulatory progress, including statements about its ongoing or planned clinical trials.

Actual results could differ materially from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process, and other risks described in the Risk Factors section of Vaxart's most recently filed Annual Report on Form 10-K and other periodic reports filed with the SEC. Vaxart undertakes no obligation to update any forward-looking statements after the date of this call.

I'll now turn the call over to Andrei Floroiu. Andrei?

Andrei Floroiu

Thank you, Ed, and thank you to all of you for joining us today. On today’s call our team will highlight the progress we have made on our norovirus oral pill vaccine program during the quarter. We will also discuss updates on our plans for an oral pan-betacoronavirus vaccine and showcase data that demonstrates the unique benefits of our platform.

Starting with norovirus, most notably in the quarter, we initiated our Phase 2 dose ranging study for our bivalent norovirus oral vaccine candidate. We remain on track to deliver on our planned milestones for 2023 with anticipated data results for both the dose ranging study and for our ongoing Phase 2 CHALLENGE study of our G11 monovalent norovirus vaccine candidate later this year.